BDBM387819 2-((1r,4r)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile::US10294226, Compound Ex. 2::US10487083, Example 2::US10981911, Example 2

SMILES N#CC[C@H]1CCC(CC1)n1c(nc2cnc3[nH]ccc3c12)-c1c[nH]cn1

InChI Key InChIKey=GJBSQXREQHZZIS-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 387819   

TargetTyrosine-protein kinase JAK1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 0.200nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 33.9nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1.5nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 33.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 33.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent